166 related articles for article (PubMed ID: 30243480)
1. [Metastatic stomach cancer: Clinical trials in Asia and in Occident].
Bui QL; Grazziotin-Soares D; Hasiniatsy RE; Trinh HS; Richard S; Lotz JP; Gligorov J; Khalil A
Bull Cancer; 2018 Oct; 105(10):932-943. PubMed ID: 30243480
[TBL] [Abstract][Full Text] [Related]
2. Recent insights in the therapeutic management of patients with gastric cancer.
de Mestier L; Lardière-Deguelte S; Volet J; Kianmanesh R; Bouché O
Dig Liver Dis; 2016 Sep; 48(9):984-94. PubMed ID: 27156069
[TBL] [Abstract][Full Text] [Related]
3. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
4. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
6. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.
Roviello G; Polom K; Petrioli R; Marano L; Marrelli D; Paganini G; Savelli V; Generali D; De Franco L; Ravelli A; Roviello F
Tumour Biol; 2016 Jan; 37(1):127-40. PubMed ID: 26566626
[TBL] [Abstract][Full Text] [Related]
8. Targetting esophageal and gastric cancers with monoclonal antibodies.
Norguet E; Dahan L; Seitz JF
Curr Top Med Chem; 2012; 12(15):1678-82. PubMed ID: 22978338
[TBL] [Abstract][Full Text] [Related]
9. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
10. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.
Tirino G; Pompella L; Petrillo A; Laterza MM; Pappalardo A; Caterino M; Orditura M; Ciardiello F; Galizia G; De Vita F
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205505
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab: in HER2-positive metastatic gastric cancer.
Croxtall JD; McKeage K
Drugs; 2010 Dec; 70(17):2259-67. PubMed ID: 21080742
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
Yi JH; Kang JH; Hwang IG; Ahn HK; Baek HJ; Lee SI; Lim DH; Won YW; Ji JH; Kim HS; Rha SY; Oh SY; Lee KE; Lim T; Maeng CH; Kim MJ; Kim ST; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
Cancer Res Treat; 2016 Apr; 48(2):553-60. PubMed ID: 26323641
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for gastric cancer: Current status and future directions (Review).
Yuan DD; Zhu ZX; Zhang X; Liu J
Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
Lordick F
Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
[TBL] [Abstract][Full Text] [Related]
16. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
17. HER2 directed therapy for gastric/esophageal cancers.
Won E; Janjigian YJ; Ilson DH
Curr Treat Options Oncol; 2014 Sep; 15(3):395-404. PubMed ID: 24811128
[TBL] [Abstract][Full Text] [Related]
18. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab for gastric cancer.
Meza-Junco J; Au HJ; Sawyer MB
Expert Opin Biol Ther; 2009 Dec; 9(12):1543-51. PubMed ID: 19916733
[TBL] [Abstract][Full Text] [Related]
20. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
